1. Market Research
  2. > Lung Injury – Pipeline Review, H1 2013

Lung Injury – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 94 pages

Lung Injury – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Lung Injury - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Injury. Lung Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Injury.
- A review of the Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lung Injury pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lung Injury.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lung Injury pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Lung Injury - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Lung Injury Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Lung Injury 10
Lung Injury Therapeutics under Development by Companies 12
Lung Injury Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Lung Injury Therapeutics - Products under Development by Companies 19
Lung Injury Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Lung Injury Therapeutics Development 22
GlaxoSmithKline plc 22
Quark Pharmaceuticals, Inc. 23
Discovery Laboratories, Inc. 24
Silence Therapeutics plc. 25
Merck KGaA 26
REVOTAR Biopharmaceuticals AG 27
Altor BioScience Corporation 28
Mondobiotech Holding AG 29
Implicit Bioscience Limited 30
KYORIN Pharmaceutical Co., Ltd. 31
Ikaria Inc. 32
Techpool Bio-Pharma Co., LTD. 33
Faron Pharmaceuticals, Ltd. 34
APEPTICO Forschung und Entwicklung GmbH 35
Lung Injury - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
dilmapimod - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
lucinactant - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
ALT-836 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Respiratory And Inflammatory Diseases Program - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
bimosiamose disodium - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
IK-6002 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
KRP-109 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
GSK-2586881 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
etanercept - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Atu-111 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
interferon beta-1a - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
interferon beta-1a - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
rosuvastatin calcium - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
PanCyte - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
AP-301 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
GSK-1995057 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
New Generation Program - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
AS-605240 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
DasKloster-1000-04 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
DasKloster-014101 - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
isoflurane - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
T-0901317 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
Drug Targeting Leptin - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
TP-405 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
Xib-1301 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Nanocurcumin - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
Lung Injury Therapeutics - Drug Profile Updates 77
Lung Injury Therapeutics - Discontinued Products 84
Lung Injury Therapeutics - Dormant Products 85
Lung Injury - Product Development Milestones 86
Featured News and Press Releases 86
Oct 17, 2012: Aeolus Pharma's AEOL 10150 Supresses Overexpression Of 31 Hypoxia-Related Genes Caused By Radiation Exposure 86
Sep 27, 2012: Discovery Labs Initiates Research Projects With Research Institutions And US Government Agencies To Assess KL(4) Surfactant Utility In Acute Lung Injury 87
Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 88
May 21, 2012: Faron Pharma Announces Presentation Of New data From ALI/ARDS FPCLI001 Study At 2012 AmericanThoracic Society Meeting 88
Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients 89
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 89
Nov 08, 2011: Silence Provides Development Update Of Atu134 90
Oct 25, 2011: APEPTICO Successfully Completes Phase I Trial With AP301 In Oedematous Respiratory Failure 91
Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries 91
Jul 19, 2011: P2D Bioscience Receives NIH Funding To Develop Drugs For Lung Disease 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 94
Disclaimer 94



List of Tables

Number of Products Under Development for Lung Injury, H1 2013 10
Products under Development for Lung Injury - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Investigation by Universities/Institutes, H1 2013 14
Comparative Analysis by Late Stage Development, H1 2013 15
Comparative Analysis by Mid Clinical Stage Development, H1 2013 16
Comparative Analysis by Early Clinical Stage Development, H1 2013 17
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Development by Companies, H1 2013 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2013 21
GlaxoSmithKline plc, H1 2013 22
Quark Pharmaceuticals, Inc., H1 2013 23
Discovery Laboratories, Inc., H1 2013 24
Silence Therapeutics plc., H1 2013 25
Merck KGaA, H1 2013 26
REVOTAR Biopharmaceuticals AG, H1 2013 27
Altor BioScience Corporation, H1 2013 28
Mondobiotech Holding AG, H1 2013 29
Implicit Bioscience Limited, H1 2013 30
KYORIN Pharmaceutical Co., Ltd., H1 2013 31
Ikaria Inc., H1 2013 32
Techpool Bio-Pharma Co., LTD., H1 2013 33
Faron Pharmaceuticals, Ltd., H1 2013 34
APEPTICO Forschung und Entwicklung GmbH, H1 2013 35
Assessment by Monotherapy Products, H1 2013 36
Assessment by Stage and Route of Administration, H1 2013 38
Assessment by Stage and Molecule Type, H1 2013 40
Lung Injury Therapeutics - Drug Profile Updates 77
Lung Injury Therapeutics - Discontinued Products 84
Lung Injury Therapeutics - Dormant Products 85



List of Figures

Number of Products under Development for Lung Injury, H1 2013 10
Products under Development for Lung Injury - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 14
Late Stage Products, H1 2013 15
Mid Clinical Stage Products, H1 2013 16
Early Clinical Stage Products, H1 2013 17
Pre-Clinical Stage Products, H1 2013 18
Assessment by Monotherapy Products, H1 2013 36
Assessment by Route of Administration, H1 2013 37
Assessment by Stage and Route of Administration, H1 2013 38
Assessment by Molecule Type, H1 2013 39
Assessment by Stage and Molecule Type, H1 2013 40

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.